ARTICLE | Strategy
Celgene's Juno juggernaut
Why Celgene, Juno are pooling forces in giant immuno-oncology deal
July 13, 2015 7:00 AM UTC
In just a few months, Celgene Corp.'s long game in hematologic malignancies has become clear: a focus on immuno-oncology. A billion dollar decade-long collaboration with Juno Therapeutics Inc. is the big biotech's most recent deal to collect different mechanisms of immune modulation that it can use to develop T cell-related biology and treatments.
Celgene had previously partnered with bluebird bio Inc. to develop chimeric antigen receptor (CAR) T cell therapies, but in June announced it was narrowing the collaboration to a single program targeting tumor necrosis factor (TNF) receptor superfamily member 17 (TNFRSF17; BCMA; CD269)...